Congratulations to Dr. Eric Vick, recipient of the Leukemia & Lymphoma Society Career Development Program award! This funding will significantly enhance research efforts aimed at treating patients with previously untargetable myeloid malignancies.
Starczynowski Research Lab at Cincinnati Children's Hospital
Hospitals and Health Care
Cincinnati, OH 173 followers
Developing scientists and improving health outcomes through curiosity, collaboration, and global sustainability
About us
The Starczynowski Laboratory is interested in the molecular, cellular, and genetic basis of hematologic malignancies, with a specific focus on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). MDS is a hematopoietic stem cell (HSC) disorder resulting in abnormal blood cell production and a propensity to progress to AML. Unfortunately, the complexity and heterogeneity of MDS and lack of mouse models has impeded our understanding and treatment of this disease. The long-term objective of the Starczynowski laboratory is to identify altered genes and signaling pathways, and understand the contribution of these alterations to the pathogenesis of MDS and AML. The overarching goal is to eventually provide novel therapies to patients with myeloid malignancies. (Our views are our own)
- Website
-
https://www.cincinnatichildrens.org/research/divisions/e/ex-hem/labs/starczynowski
External link for Starczynowski Research Lab at Cincinnati Children's Hospital
- Industry
- Hospitals and Health Care
- Company size
- 11-50 employees
- Headquarters
- Cincinnati, OH
- Type
- Nonprofit
- Founded
- 2010
- Specialties
- myelodysplastic syndromes, acute myeloid leukemia, hematologic malignancies, hematopoietic stem cells, hematopoiesis, innate immunity, and therapy resistance
Locations
-
Primary
Get directions
Cincinnati, OH, US
Employees at Starczynowski Research Lab at Cincinnati Children's Hospital
Updates
-
The Starczynowski Lab is excited to share our latest paper in iScience describing the complex role of dysregulated innate/inflammatory signaling in the progression of MDS to AML with RUNX1 mutations. https://lnkd.in/gp6pS_Na Congrats to lead author Laura Barreyro for spearheading the project. We are grateful to the insightful reviewers, our collaborators, and for support from CancerFreeKids, Leukemia and Lymphoma Society, NIH, UCCC, and CCHMC. Our study shows loss of miR146a - a commonly deleted gene in MDS - and mutant RUNX1 initially induce MDS and then progress to AML. At the AML stage, RUNX1 mutant rewires inflammatory pathways. Inhibiting immune signaling suppresses leukemic cells, highlighting the role of immune dysregulation at initiation and later stages of AML. These results provide evidence that dysregulation of innate immune and inflammatory signaling is essential for propagating pre-leukemic cells and contributes to the progression of AML. #LeukemiaResearch #AML #MDS #Inflammation #miR146a #RUNX1
-
-
A heartfelt thank you to The Live Like Maya Foundation for their invaluable contribution to the new Advanced Leukemia Therapies and Research Center (ALTRC) at Cincinnati Children’s. Your support fosters hope and progress, and extends far beyond the laboratory, touching the lives of countless individuals also impacted by myeloid malignancies. Learn about the foundation here: www.LiveLikeMaya.org Learn about ALTRC here: https://lnkd.in/eniKikMy #AdvancedLeukemiaTherapiesAndResearchCenter #CCHMC #cancerresearch Cincinnati Children's
-
-
Applauding the incredible efforts of Jan Rosenbaum as she leads Kurome Therapeutics, Inc. towards bringing groundbreaking cancer therapeutics to clinical trials. Her tireless commitment is no doubt shaping a brighter future for patients! Read on to learn more about her
Nice write up about Kurome Therapeutics in today's Cincinnati Business Courier. #cancerresearch #cancertreatment #AML #drugdevelopment #startups #drugdiscovery
-
GREEN THOUGHT! 9 tips for avoiding single use plastics, credit to lessplastic.co.uk
-
-
Please join us in congratulating 🌟StarLab🌟 members Chiharu Ishikawa and Issac Choi! Chiharu recently received funding from CancerFree KIDS for her work on “Developing novel UBE2N inhibitors for cancer using DNA-encoded library screens.” Issac is the recipient of the UC Cincinnati College of Medicine’s Environmental Carcinogenesis and Mutagenesis Training Grant We are grateful for the continued support of these indispensable and generous organizations! Cincinnati Children's CancerFree KIDS University of Cincinnati College of Medicine
-
-
Green Thought- ways to reduce your lab's carbon footprint! https://lnkd.in/eBK4QNv9 https://lnkd.in/detmPdB8 https://lnkd.in/gkjZnkVi
-